ABBREVIATIONS. CPAP, nasal continuous positive airway pressure; aAPo 2 , arterial to alveolar oxygen tension ratio; RDS, respiratory distress syndrome; Fio 2 , fraction of inspired oxygen.
T he laboratory and clinical investigation of exogenous pulmonary surfactant therapy for respiratory distress syndrome (RDS) in preterm infants is one of the most comprehensive therapeutic adventures in neonatal medicine of this decade. Mortality in the very low birth weight infant with RDS clearly has improved along with a reduction in the incidence of pulmonary interstitial emphysema, pneumothorax, and bronchopulmonary dysplasia.
One issue that remains unresolved is the use of surfactant as prophylaxis versus rescue therapy in infants with established disease. Installation before or at the initiation of respiration is no longer believed to be essential for successful intrapulmonary distribution or clinical response; however, early treatment of infants with RDS may be beneficial.
Clearly, gestational age and birth weight are directly related to endogenous surfactant production. However, multiple variables including maternal steroid administration, duration of ruptured membranes, amniotic fluid volume, intrauterine growth, infection, and other forms of intrauterine stress make the decision to treat a clinical one rather than a decision based on gestational age and birth weight alone. Unfortunately, no rapid test for identification of surfactant deficiency has emerged, and clinical features of grunting, nasal flaring, and retracting, plus radiographic features and oxygen needs remain the mainstay for evaluation of disease severity.
In this issue of Pediatrics electronic pages, Verder and colleagues 1 extend their observations on the early use of surfactant for the treatment of established RDS. This group demonstrated previously that surfactant therapy given to infants with moderate to severe RDS receiving nasal continuous positive airway pressure (CPAP) reduced the need for mechanical ventilation. 2 The current study extends and confirms those observations in infants Ͻ30 weeks' gestation.
The measure of disease severity in both studies was the arterial to alveolar O 2 oxygen tension ratio (aAPo 2 ). The earlier study group 2 had an aAPo 2 of 0.17 at randomization, with a rise to 0.37 Ϯ 0.15 in the surfactant-treated group 6 hours after therapy, compared with 0.25 Ϯ 0.10 in untreated control subjects. Subsequent mechanical ventilation was required in 43% (15/35) and 85% (28/33), respectively (P ϭ .003). In the current study, the aAPo 2 was 0.26 Ϯ 0.06 at the time of surfactant therapy in the early-treated group and 0.16 Ϯ 0.04 in the late-treated group (P ϭ .0001). The 6-hour aAPo 2 response was greater in the earlytreated group, 0.48 Ϯ 0.18 versus 0.36 Ϯ 0.18 in the late-treated group (P ϭ .02). Fewer early-treated infants required mechanical ventilation or died within 7 days of age, 21% (7/33) versus 63% (17/27) (P ϭ .0013). The authors conclude from the current study that although approximately half of infants Ͻ30 weeks' gestational age with RDS can be treated with nasal CPAP alone, early treatment with surfactant when the aAPo 2 is 0.22 to 0.36 reduced significantly the need for mechanical ventilation.
The use of the aAPo 2 as an estimate of gas exchange and severity of pulmonary disease is an old technique 3 with a relatively newer variation; ie, the estimate of Pao 2 with a transcutaneous monitor. A major variable in the reports of the Danish collaborative studies is the use of transcutaneous Po 2 measurements as estimates of Pao 2 . No data are provided to compare these measurements because Pao 2 was not measured routinely. However, other reports 4, 5 indicate at least a 10 TORR standard deviation in transcutaneous measurements, suggesting that absolute values of aA ratios may vary considerably from those determined by arterial samples. The effect of nasal CPAP on arterial oxygenation also is uncertain and, therefore, the applicability of specific aA ratios in the Danish studies to values obtained from arterial samples in infants receiving oxygen delivered within a hood is unknown.
Almost all modern blood gas machines now use co-oximetry with measurement (rather than estimation) of hemoglobin and oxygen saturation in addition to pH, Pco 2 , and Po 2 . Providing Fio 2 , therefore, allows calculation of the aA ratio, AaDo 2 , and oxygen content, which are available as reported values.
The magnitude of the effect of measurement of Po 2 on aA ratios at inspired O 2 concentrations from 0.3 to 0.5 is shown in Table 1 . The Verder et al data suggest that all infants Ͻ30 weeks' gestation with RDS requiring an Fio 2 Ն0.5 would benefit from surfactant. However, there may be considerable variation among infants qualifying to receive surfactant whose Fio 2 is 0.3 to 0.5. Therefore, the precision of the measurement may affect the number of infants receiving early surfactant treatment.
The variations in transcutaneous o 2 determinations likely affected infants similarly in early-and late-treated patients in the current study and do not detract from the value of the results. Early treatment is better than late treatment. Unfortunately, both studies fell short of the projected number of subjects planned. Additional data involving patients with and without nasal CPAP, ie, those receiving hood o 2 and correlation of transcutaneous with arterial Po 2 , would be helpful. In the meantime, data are mounting that spontaneously breathing, very low birth weight infants with RDS will benefit from surfactant therapy when the aAPo 2 is Ͻ0.36 corresponding to Fio 2 Ͻ0.5. The observation supplements existing recommendations that infants with RDS requiring mechanical ventilation receive surfactant when the aAPo 2 is Ͻ0.22. 
